Popular Articles

NHLBI Funds Global Centers On Chronic Diseases And Collaborates With UnitedHealth Group
NHLBI Funds Research and Training Centers Aimed at Prevention and Treatment of Chronic Diseases in Developing Countries and Collaborates with UnitedHealth Group"s Chronic Disease Initiative
generic viagra online
Opinion: Obama's Africa Policy; Maternal Health
President Obama is expected to arrive in Accra, Ghana, Friday night, the AP/Google.com reports. White House adviser Michelle Gavin said the president chose to travel to Ghana "because it"s such an admirable example of strong, democratic governance, vibrant civil society" (Babington, 7/10). The following are opinion pieces reflecting on his trip and Africa policy:
News of the day
PolyMedix Receives Regulatory Clearance To Initiate Second Phase I Clinical Study Of Novel Systemic Antibiotic Compound
PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has received a notice of no objection from Health Canada for the Company"s Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of the second human clinical study in Canada. PMX-30063 is a defensin mimetic antibiotic compound, the first of an entirely new class of antibiotic drugs that is believed to work in such a way that makes bacterial resistance unlikely to develop.
Medical Devices

Medicare Part D Healthy For Enrollees

Medicare beneficiaries" activities of daily living (ADL) improved in their first year of the Medicare Part D senior prescription drug plan, according to a ground-breaking study presented at the Annual AcademyHealth meetings in Chicago today. In a study of Medicare records, University of Maryland School of Pharmacy researchers found that Part D in 2006 resulted in "small but statistically significant" improvements in the health status of previously uninsured beneficiaries and in their access to medications. Nearly two-thirds of people with no drug coverage in 2005, before the plan, enrolled in Part D in 2006, the most recent year of available files from the Medicaid Current Beneficiary Survey. "It"s a rich of information about beneficiary characteristics, health status, and activity limitations," said study leader, Amy Davidoff, PhD, research assistant professor at the School. "These individuals arguably had the most to gain from the new program, and thus represent an obvious population of policy interest." Previous studies of Part D focused mainly on enrollment patterns, ease of access and beneficiary options. "Much less is known about the impact of Part D on the health and well being of beneficiaries who enrolled. It will be years before definitive answers are available, but it is now possible to assess selected potential short-term health benefits associated with Part D," said Bruce Stuart, PhD., professor, and director of the School"s Peter Lamy Center on Drug Therapy and Aging. The study also revealed that Part D enrollees experienced twice as much improvement, 8 percent, in their financial hardships than non-enrollees, 4 percent. And, non-enrollees were 3 percent less likely to report improved health in 2006 compared to 2005, relative to enrollees. Both groups reported similar counts of ADL limitations in 2005 but they declined for Part D enrollees, and increased for non-enrollees. "Our findings suggest that in its inaugural year, the program was modestly successful in achieving its stated aims," said Stuart. "The program, now in its fourth year, needs further study to determine whether the short-term gains we identified were maintained or improved further." Medicare Part D is a federal program that subsidizes the costs of prescription drugs for Medicare beneficiaries. It is part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). Part D went into effect on January 1, 2006. The team presented two posters this morning at the AcademyHealth meetings.The study was funded by Novartis Parmaceuticals, Corp. University of Maryland Baltimore


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):